STOCKHOLM, Sept. 14, 2026 /PRNewswire/ — During the period September 7 – September 11, 2026, Telefonaktiebolaget LM Ericsson(publ) (“Ericsson“) (LEI code 549300W9JLPW15XIFM52) repurchased own Class B shares (ISIN: SE0000108656) as follows:

The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026, and which runs between April 23, 2026, and March 31, 2027, at the latest. The Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares, other than those used to fulfil Ericsson’s obligations under its share-related incentive programs, are cancelled.

The share buyback program is executed in accordance with the Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing MAR (the Safe Harbour Regulation).

All acquisitions have been carried out on Nasdaq Stockholm by Goldman Sachs Bank Europe SE on behalf of Ericsson. A full breakdown of the transactions is attached to this announcement.

Following the repurchases above, Ericsson’s holding of treasury stock amounts to 107,518,663 Class B shares. There are in total 3,371,351,735 shares in Ericsson, 261,755,983 shares of Class A and 3,109,595,752 shares of Class B.

NOTES TO EDITORS:

FOLLOW US:
Subscribe to Ericsson press releases
Subscribe to Ericsson blog posts
https://x.com/ericsson
https://www.facebook.com/ericsson
https://www.linkedin.com/company/ericsson

MORE INFORMATION AT:
Ericsson Newsroom
[email protected]  (+46 10 719 69 92)
[email protected]  (+46 10 719 00 00)

Investors
Daniel Morris, Vice President, Head of Investor Relations
Phone: +44 7386 657217
E-mail: [email protected]

Lena Häggblom, Director, Investor Relations
Phone: +46 72 593 27 78
E-mail: [email protected]

Media
Ralf Bagner, Head of Media Relations
Phone: +46761284789
E-mail: [email protected]

ABOUT ERICSSON:
Ericsson’s high-performing, programmable networks provide connectivity for billions of people every day. For 150 years, we’ve been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ericsson/r/share-buybacks-in-ericsson-during-the-period-september-7—september-11–2026,c4395255

The following files are available for download:

View original content:https://www.prnewswire.com/apac/news-releases/share-buybacks-in-ericsson-during-the-period-september-7—september-11-2026-302877363.html

SOURCE Ericsson

YANTAI, China, Sept. 14, 2026 /PRNewswire/ — Sungrow, a global leading renewable energy company, recently hosted the latest edition of its PhD Talk series in China’s Bohai Bay, bringing together experts and industry representatives in offshore PV, island microgrids, deep-water offshore wind and marine conservation.

Under the theme “The Power of Bridge: Bridge to The Deep Blue,” the event identified five key trends shaping offshore renewables in the move from demonstration projects toward commercial deployment.

Offshore systems must withstand salt spray, high humidity, waves, tides and typhoons while navigating limited operation and maintenance (O&M) windows, insufficient grid support and coordination across multiple types of equipment.

Trend 1: Scenario-Defined Design Replaces a One-Size-Fits-All Approach

Offshore equipment cannot simply replicate land-based products, and different marine environments demand different designs. David Sun, General Manager of the R&D Center at Sungrow’s Utility PV Business Unit, noted that tropical waters bring heat and humidity, cold-water environments create condensation risks, and nearshore industrial zones expose equipment to chemical corrosion.

Sungrow therefore uses a unified, high-standard technology platform while adapting materials, sealing processes and thermal management strategies to local conditions.

Trend 2: AI-Powered Reliability Supports Offshore Solar’s Move to Commercial Scale

As offshore PV moves from demonstration projects toward commercial operation, harsher environmental loads and mounting cost pressures remain key challenges, according to Hui Xing, Chief Engineer of POWERCHINA Northwest Engineering Corporation Limited’s New Energy Engineering Institute.

David further emphasized that project economics extend beyond upfront equipment costs to downtime, offshore inspections and long-term maintenance. Sungrow’s Smart IV Curve Diagnosis identifies string faults, while self-learning algorithms monitor inverter air-duct health, enabling early warnings and dust removal. MPPT-level insulation detection reduces fault-location time to one-sixth of that required by conventional inverter-level diagnosis, while AI-based fault localization pinpoints issues to individual modules within a string.

Trend 3: Lifecycle Reliability and Proactive Safety Become Core Design Requirements

The SG465HX utility string inverter incorporates IP66 protection, C5-H corrosion resistance, a fully sealed electronics chamber, an IP68-rated fan, weather-resistant sealing materials and intelligent active dehumidification.

In a 1,440-hour cyclic neutral salt spray test (two hours in 5% sodium chloride spray and 22 hours at 40±2°C and 93% relative humidity per cycle), no corrosion appeared on the enclosure, structural parts or core internal components. Sungrow also received a third-party C5-H certification report.

The inverter’s proactive safety features include intelligent string shutdown, AC and DC terminal temperature monitoring, a DC switch with a trip mechanism, and 24-hour insulation monitoring. Sungrow also developed two-stage waterproof terminal caps for protection during transportation, construction and long-term operation, including IP68-rated PA66 caps for unused terminals. A dedicated offshore DC switch uses corrosion- and wear-resistant coatings to reduce the risk of contact sticking and failure to interrupt fault current caused by salt spray.

Trend 4: Grid-Forming Technology Becomes the Backbone of Island Microgrid Stability

Island microgrids face three core challenges: generation uncertainty, load uncertainty and the absence of external grid support, making grid-forming technology and coordinated power-system control essential to stable power supply, according to Dr. Liu Hangyue, Deputy General Manager of Sungrow’s Microgrid and Grid Solutions Center.

David said Sungrow’s inverter portfolio offers grid-forming capability under all grid conditions, letting PV inverters in microgrids establish voltage and support frequency through grid-forming algorithms. In PowerMatrix, each sub-array can operate independently in grid-forming mode, enabling 10-millisecond voltage stabilization and a 5-millisecond inertia response.

Future island energy systems will require coordinated control across solar, wind, storage, the grid and loads, rather than relying on individual devices alone.

Trend 5: Deep-Water Offshore Wind Shifts from Equipment Adaptation to System-Level Co-Design

As offshore wind expands into deeper waters and farther from shore, the challenge is shifting from individual-device reliability to system-wide coordination and value-chain collaboration. Larger turbines can reduce costs and improve efficiency but introduce new issues involving fluid-structure interaction, material properties and multidisciplinary coordination, according to Xu Guodong, Deputy Chief Engineer of Windey Energy Technology Group.

Addressing this shift, Dr. Wang Lingxiang, Vice President of Sungrow and President of its Wind Energy Business Unit, said deep-water sites, evolving power-system requirements and complex marine conditions place greater demands on the reliability, overload capability and intelligent O&M of wind converters.

Electrical equipment must move from passive adaptation to active integration through system-level co-design with generators, cables and transformers, as well as participation in turbine load control and intelligent shutdown strategies. Grid-forming applications must also reflect specific grid-connection and power-transmission configurations, strengthening grid support while safeguarding generators and managing turbine loads. Hardware upgrades should be based on system design requirements.

Beyond technology, Sungrow Foundation joined WWF and the One Planet Foundation to launch a marine “Sun Forest” ecological restoration initiative in Bohai Bay, aiming to restore seagrass and macroalgal beds to improve marine habitats. The foundation also donated a 10.35 kW/10 kWh solar-plus-storage system, expected to generate approximately 12,000 kWh annually, to support emergency and stable power supply for an island community.

This edition of Sungrow’s PhD Talk series traced the industry’s shift from a focus on individual equipment performance toward scenario-specific design, lifecycle reliability, intelligent O&M and system-wide coordination. To support this transition, Sungrow will continue exploring solutions for different marine environments and energy applications through innovation in power conversion and grid technologies.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/sungrow-phd-talk-outlines-5-key-trends-in-offshore-renewables-302877348.html

SOURCE Sungrow

CHENGDU, China, Sept. 14, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”, 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) trastuzumab botidotin (舒泰莱^®) in HER2-positive unresectable or metastatic breast cancer (BC) have been published in Journal of Clinical Oncology (JCO, impact factor (IF)=44.7). Professor Xichun Hu and Professor Hongxia Wang of Fudan University Shanghai Cancer Center, and Dr. Junyou Ge, Director of the National Engineering Research Center of Targeted Biologics act as the co-senior authors. Professor Jian Zhang of Fudan University Shanghai Cancer Center, Professor Quchang Ouyang of Hunan Cancer Hospital, Professor Qingyuan Zhang of Harbin Medical University Cancer Hospital, Professor Huihui Li of Cancer Hospital of Shandong First Medical University, and Professor Xu Wang of Tianjin Medical University Cancer Institute and Hospital act as the co-first authors. These findings had previously been selected as a Late-Breaking Abstract (LBA) and presented as an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.

This randomized, open-label, multicenter phase III study was designed to evaluate the efficacy and safety of trastuzumab botidotin monotherapy versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic BC who had received prior trastuzumab and taxane-containing regimens. A total of 365 patients were randomized 1:1 to receive trastuzumab botidotin or T-DM1. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR), and secondary endpoints included overall survival (OS), objective response rate (ORR), and duration of response (DoR).

As of the data cutoff date of April 26, 2025, with a median follow-up of 14.9 months, efficacy results showed:

• Median PFS was significantly prolonged in the trastuzumab botidotin group compared with the T-DM1 group (11.1 months vs. 4.4 months; hazard ratio (HR) = 0.39) (Figure A), meeting the primary endpoint of the study; consistent PFS benefit was observed across all prespecified subgroups (Figure B).
   
•  Trastuzumab botidotin group demonstrated deeper and more durable tumor responses compared with T-DM1 group, with an ORR of 76.9% vs. 53.0% and a median DoR of 12.2 months vs. 5.7 months (Figure C).
•  OS data were not mature in both groups, but an OS benefit trend was observed in trastuzumab botidotin group, demonstrating a 38% reduction in the risk of death (Figure D).

In terms of safety, patients in the trastuzumab botidotin group had a low incidence of interstitial lung disease (ILD), and the incidences of hematologic, hepatic, and gastrointestinal toxicities were notably lower than those in the T-DM1 group, along with lower rates of serious adverse events (SAEs) and treatment discontinuations. The most common treatment-related adverse events (TRAEs) in trastuzumab botidotin group were ocular events, which could be recovered or reversed after management with standardized strategies.

The publication of the phase III results for trastuzumab botidotin in Journal of Clinical Oncology marks a major international academic breakthrough for a domestically developed HER2 ADC backed by high-level clinical evidence. This is the first phase III trial in China for a HER2 ADC compared head-to-head with T-DM1 with positive results. The data showed that trastuzumab botidotin demonstrated improvements in key efficacy endpoints including PFS, ORR, and DoR, along with a favorable safety profile. Based on these positive results, trastuzumab botidotin has been approved by China’s National Medical Products Administration (NMPA) for the treatment of second-line or later HER2-positive BC, becoming the first domestically developed HER2 ADC approved for this indication in China and providing a new treatment option for patients with HER2-positive advanced breast cancer.

About Trastuzumab botidotin(舒泰莱^®)

Trastuzumab botidotin is a differentiated HER2 ADC to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, monomethyl auristatin F (MMAF) derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a multi-center, randomized, open-label, controlled Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with unresectable or metastatic HER2 positive BC who have received one or more prior anti-HER2 therapy. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS as assessed by the BICR compared with T-DM1; the beneficial trend for OS of trastuzumab botidotin was also observed.

Currently, the Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor payload ADC.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/results-from-phase-iii-study-of-trastuzumab-botidotin-versus-t-dm1-in-her2-positive-breast-cancer-published-in-jco-302877338.html

SOURCE Kelun-Biotech

XIAMEN, China, Sept. 14, 2026 /PRNewswire/ — Curated by the Italian Trade Agency (ITA) in collaboration with Ministry of Foreign Affairs and International Cooperation (MAECI) and jointly with the Ministry of Enterprises and Made in Italy (MIMIT), the Italy National Pavilion officially opened at 12:00 on September 8 during the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Official representatives from China and Italy attended the opening ribbon-cutting ceremony. Under the theme “Italy: A Land of Opportunities”, Italy showcased its investment value and cooperation potential to the Chinese market at this edition of CIFIT.

As the world’s eighth-largest economy and the EU’s second-biggest manufacturing nation, Italy offers mature FDI support policies and robust industrial bases. At CIFIT, multiple Italian authorities showcased Italy as a key European investment hub for Chinese firms, introducing full-cycle one-stop government services, local investment rules, incentives, business climate and premium opportunities.

Focusing on automotive, aerospace, green supply chains, circular economy and life sciences, the booth presented free-trade zone industrial policies and incentives, alongside a curated list of high-quality Italian real estate projects. Investment guides covering procedures, project proposals and benefits were available on site.

Throughout CIFIT, the professional investment teams composed of senior officers from the Technical Secretariat of the Committee for the Attraction of Foreign Investment (STCAIE) and the Special Unit for Attracting and Unblocking Investments (UMASI) under the Ministry of Enterprises and Made in Italy, China-based representatives of the Invest in Italy initiative (including the FDI Desk Beijing and FDI Desk Hong Kong of ITA), as well as expert teams from Invitalia, held multiple B2B meetings with interested Chinese enterprises, providing face-to-face one-stop investment advisory services.

A series of seminars were hosted within the pavilion. Among them, the special seminar titled “ITALIAN FDI ATTRACTION POLICIES AND OPPORTUNITIES“ held on the afternoon of September 8 drew more than 200 audiences. Italian speakers shared insights on full-cycle supporting services for foreign investors in Italy and offered an in-depth interpretation of Italy’s foreign direct investment support system.

Amedeo Teti, Director-General of STCAIE of MIMIT, gave a comprehensive overview of Italy’s new framework for attracting foreign investment. Augusto Reggiani, Director of Italian Foreign Investments Attraction Unit – INVESTMENT SCREENING EXPERT GROUP in MIMIT, elaborated on tailored investment opening measures for investors. Giovanni Savini, Director of UMASI of MIMIT, outlined the unit’s role in facilitating the implementation of major investment projects of national strategic significance. A Q&A session followed the seminar, enabling in-depth exchanges between participating enterprises and speakers.

Besides the flagship seminar, on September 9 two smaller investment promotion sessions were co-hosted by Invitalia and ITA’s investment promotion division. The sessions covered foreign investment opportunities in automotive, aerospace, green supply chains, life sciences and circular economy, and illustrated Italy’s unique competitive advantages as an EU manufacturing base.

Cultural experience activities will also be arranged at the pavilion, featuring tastings of Italian fine wine and Padano cheese. Italian coffee and Made in Italy ice cream will be served throughout the days, vividly presenting Italian lifestyle.

According to relevant officials of ITA, the participation achieved fruitful results. CIFIT served as an efficient platform where Chinese enterprises interested in investing in Italy obtained first-hand advice directly from Italian investment specialists, further strengthening their intention to invest in Italy. Italy attaches great importance to economic and trade ties with China and warmly welcomes Chinese enterprises to invest in Italy. After the fair, ITA China-based offices and FDI Desk Beijing and FDI Desk Hong Kong of ITA will continue to provide investment advisory services for market entities considering Italy.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/italy-national-pavilion-shines-at-the-26th-china-international-fair-for-investment-and-trade-302877298.html

SOURCE Italian Trade Agency (ITA)

STOCKHOLM, Sept. 14, 2026 /PRNewswire/ — Systecon, the global leader in analysis-driven life cycle management (LCM), today announces the availability of a new release of Opus Suite+, its unified decision-support software for life cycle analysis. The release is a real step beyond the complex system optimization and simulation OPUS10 and SIMLOX made possible on their own, and Systecon is encouraging customers running those tools to make the move now.

The new release cuts the time from analysis to better decisions. Visibility into complex systems is instant, not buried in data. Model work moves faster with fewer errors caught later. And teams can act on results immediately instead of spending time decoding software output.

This latest release of Opus Suite+ also sees the introduction of AI as an integrated support partner. AI in Opus Suite+ is helping our customers move faster to insights while keeping analysts in control. Rather than automating judgment, it amplifies human expertise and keeps the accountability and governance that matters in defense and critical infrastructure where it belongs: with the people making the call.

Cloud-based deployment of Opus Suite+ is also now available in this next release, enabling browser-based access and private cloud deployment. Teams can now access shared models and scale computing resources without local installation, while maintaining complete control of data, security and infrastructure.

With this new release, Systecon is inviting its wider customer base, and organizations evaluating decision-support software for life cycle analysis for the first time, to see firsthand how far Opus Suite+ has advanced, cementing its position as the gold standard for analysis-driven life cycle management (LCM) software.

“This is not simply an upgrade. It’s a real step beyond what OPUS10 and SIMLOX made possible, and we’re proud of the work that got us here,” said Anders Carlsson, CEO, Systecon. “This new release is the moment for our OPUS10 and SIMLOX customers to make that move, and for the wider market to see how far decision support for life cycle analysis has come.”

“The path from analysis to insight just got smoother,” said Johan Holmqvist, Chief Product Officer, Systecon. “Users now spend less time wrestling with the interface and more time on what matters: understanding what their analysis tells them and acting on it. With integrated AI support and cloud deployment, we’re moving teams faster while keeping their judgment in charge.”

Systecon invites current customers and organizations evaluating decision-support software for life cycle analysis to request a demonstration and see the improvements firsthand.

Don’t Guess. Know.  

For further information, please contact:
Johan Holmqvist, Chief Product Officer, Systecon
Phone: +46 708 40 59 49 | [email protected]

About Systecon

Systecon is a global leader in analysis-driven Life Cycle Management (LCM), providing advanced software and services for optimizing system cost, performance, and readiness. Since 1970, we have supported organizations worldwide with cutting-edge solutions for modelling, simulation, and cost analysis. Our world-leading Opus Suite helps users predict and optimize the impact of decisions on system performance and costs throughout the entire life cycle. Trusted by the majority of defense forces within NATO and allies, we serve aerospace and defense, enhancing operational readiness and cost efficiency.

Learn more at www.systecongroup.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/systecon-ab/r/systecon-launches-new-release-of-opus-suite–marking-a-step-change-beyond-opus10-and-simlox-for-the-,c4394377

The following files are available for download:

View original content:https://www.prnewswire.com/apac/news-releases/systecon-launches-new-release-of-opus-suite-marking-a-step-change-beyond-opus10-and-simlox-for-the-first-time-302877332.html

SOURCE Systecon AB

Central Pattaya invites runners from around the world to experience a 5K beach race combining sunset, music, entertainment and Pattaya’s vibrant beach lifestyle on 31 October 2026

PATTAYA, Thailand, Sept. 14, 2026 /PRNewswire/ — Get ready to run Thailand’s most famous beach destination after dark. Central Pattaya, a global beachfront landmark in the heart of Pattaya, invites runners and travelers from around the world to join the ‘Pattaya International Bikini Beach Race 2026: Run the wave. Own the night.‘ on 31 October 2026. Celebrating its 10th anniversary under the theme “The Sunset to Moonlight Beach Race,” the 5K race will bring thousands of runners to the sands of Pattaya Beach for a one-of-a-kind night combining sunset running, music, entertainment and Pattaya’s vibrant beach lifestyle.

Last year, the event attracted more than 5,000 runners from around the world, establishing the Pattaya International Bikini Beach Race as one of Thailand’s most popular and distinctive seaside running events.

This year, runners will take on a 5K course along Pattaya Beach, starting and finishing in front of Central Pattaya. Beginning against a spectacular seaside sunset, the race will continue into the evening as the beachfront transforms into a vibrant moonlight celebration filled with music and entertainment. Taking place on Halloween night, the 2026 edition will bring even more energy to the beach, inviting runners to dress up, stand out and be part of a colorful international running community in the heart of Pattaya.

More than just a race, the event offers international visitors a unique reason to turn race weekend into a Pattaya beach getaway. Runners can experience the city’s beaches alongside its shopping, dining, entertainment and nightlife — all within one of Thailand’s most dynamic seaside destinations.

Event: Pattaya International Bikini Beach Race 2026
Date: Saturday, 31 October 2026
Distance: 5K Beach Run
Location: Pattaya Beach, starting and finishing in front of Central Pattaya
Registration Fee: US$30.49 (THB 1,000)
Registration: Open until 30 October 2026
Click: https://worldsmarathons.com/marathon/pattaya-bikini-run

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/run-pattaya-beach-from-sunset-to-moonlight-thailands-largest-bikini-beach-race-returns-for-its-10th-anniversary-302877300.html

SOURCE CENTRAL PATTANA

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor for the treatment of multiple myeloma (MM), conducted in collaboration with the Department of Hematology at Peking University Third Hospital, has been published in Cancer Gene Therapy, an international SCI journal under Springer Nature.

Details of the Paper
Title: CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8⁺ T cells
Journal: Cancer Gene Therapy
DOI: 10.1038/s41417-026-01078-9

Study Design:

The research team first analyzed CD73 expression across multiple tumor cell lines following selinexor treatment, then tested the combination in vivo using a J558-inoculated BALB/c mouse model, with mice divided into a vehicle group, an ATG-037 monotherapy group, a selinexor monotherapy group and a combination-therapy group. Single-cell RNA sequencing was used to characterize immune cell subtypes and tumor-immune crosstalk, immunofluorescence staining was performed on tumor tissue, and a co-culture model of CD8⁺ T cells and multiple myeloma cell lines was established to confirm the mechanism behind the combination’s antitumor effect.

Key Findings: 

Selinexor treatment was found to upregulate CD73 expression in the majority of tumors, a resistance-associated mechanism that the combination approach was designed to counter. In the mouse model, the combination therapy suppressed tumor growth with an inhibition rate of 62%, compared with 31% for ATG-037 monotherapy and 43% for selinexor monotherapy. Single-cell RNA sequencing showed that the combination synergistically potentiated CD8⁺ T cell activation by enhancing the interaction between CD8⁺ T cells and Enpp1⁺ cells via the CD80–CD28 signaling pathway, and the resulting increase in CD8⁺ T cell infiltration into tumor tissue was confirmed by immunofluorescence staining. In co-culture experiments, CD73 inhibition was shown to strengthen selinexor-mediated tumor cell killing by activating CD8⁺ T cells, with significantly elevated levels of Granzyme B (P=0.0252) and IFN-γ (P=0.0067) observed in the combination group.

Conclusion:

The study highlights the synergistic potential of combining selinexor with a CD73 inhibitor for enhancing CD8⁺ T cell-mediated tumor cytotoxicity in MM. Selinexor therapy upregulates CD73 in the TME, driving adenosine accumulation and an immunosuppressive state. Combined use of ATG-037 blocks this immunosuppressive feedback loop via suppression of CD73-dependent adenosine synthesis, restoring CD8⁺ T cell activation and proliferation while enhancing T cell cytotoxicity through activation of the CD80-CD28 costimulatory axis. These findings establish a novel, clinically feasible therapeutic paradigm for addressing drug resistance and refractory MM.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene’s proprietary AnTenGager^® platform.

AnTenGager^®, is Antengene’s proprietary TCE 2.0 platform, featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 34 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

PR / IR Contacts: 
Peter Qian
E-mail: [email protected]  

BD Contacts:
Ariel Guo
E-mail: [email protected] 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/antengene-publishes-preclinical-research-paper-on-cd73-small-molecule-inhibitor-atg-037-combined-with-selinexor-in-cancer-gene-therapy-302877241.html

SOURCE Antengene Corporation Limited

Board Authorization Reflects Confidence in Solidion’s Long-Term Strategy and Commitment to Enhancing Shareholder Value

DALLAS, Sept. 14, 2026 /PRNewswire/ — Solidion Technology, Inc. (NASDAQ: STI) (“Solidion Technology” or “the Company”), an advanced battery technology solutions provider, today announced that its Board of Directors (“the Board”) has authorized a new stock buyback program, pursuant to which the Company intended to buyback up to $1.0 Million of the Company’s outstanding common stock.

The stock buyback program became effective on September 13, 2026 and will remain in effect until (i) the date on which the full amount authorized has been repurchased, (ii) March 14, 2028 or (iii) the date on which the authorization is terminated by the Board.

The authorization reflects the Board’s confidence in Solidion’s long-term strategy and provides the Company with additional flexibility in its approach to capital allocation. Solidion believes that the buybacks may represent an attractive use of capital while supporting the Company’s broader objective of creating long-term value for stockholders. Open-market repurchases are expected to be conducted in accordance with applicable federal securities laws, as well as applicable Nasdaq requirements and state law.

“The Board’s authorization of this stock buyback program reflects our confidence in Solidion’s long-term prospects and our commitment to disciplined capital allocation,” said Jaymes Winters, Chief Executive Officer of Solidion Technology. “We believe that our technology, intellectual property and strategic position provide a strong foundation for future growth. This program gives us the flexibility to act when we believe market conditions present an attractive opportunity to invest in Solidion and enhance long-term value for our stockholders.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 385 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Please follow us on:

LinkedIn: https://www.linkedin.com/company/solidion-tech
X: https://x.com/solidiontech?lang=en 

SOURCE Solidion Technology, Inc.